145 related articles for article (PubMed ID: 33090259)
1. Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy.
Reesink DJ; Schilham MGM; van der Hoeven EJRJ; Schoots IG; van Melick HHE; van den Bergh RCN
World J Urol; 2021 Jul; 39(7):2453-2461. PubMed ID: 33090259
[TBL] [Abstract][Full Text] [Related]
2. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
[TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
[TBL] [Abstract][Full Text] [Related]
6. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38402105
[TBL] [Abstract][Full Text] [Related]
7. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies.
Knaapila J; Jambor I; Ettala O; Taimen P; Verho J; Perez IM; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
Eur Urol Focus; 2021 May; 7(3):522-531. PubMed ID: 32418878
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
9. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
10. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
11. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
[TBL] [Abstract][Full Text] [Related]
12. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
Jambor I; Boström PJ; Taimen P; Syvänen K; Kähkönen E; Kallajoki M; Perez IM; Kauko T; Matomäki J; Ettala O; Merisaari H; Kiviniemi A; Dean PB; Aronen HJ
J Magn Reson Imaging; 2017 Oct; 46(4):1089-1095. PubMed ID: 28165653
[TBL] [Abstract][Full Text] [Related]
13. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of trans-rectal color doppler flow imaging and risk-stratification nomogram reduce unnecessary prostate biopsies in suspected prostate cancer patients: a bi-centered retrospective validation study.
Guo Y; Su K; Lu M; Liu X
BMC Urol; 2023 May; 23(1):81. PubMed ID: 37138271
[TBL] [Abstract][Full Text] [Related]
16. bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study.
Pan Y; Shen C; Chen X; Cao D; Jiang J; Xu W; Ji C; Pan X; Zheng B
Front Surg; 2022; 9():1096387. PubMed ID: 36726941
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?
Alberts AR; Schoots IG; Bokhorst LP; Drost FH; van Leenders GJ; Krestin GP; Dwarkasing RS; Barentsz JO; Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2018 Mar; 73(3):343-350. PubMed ID: 28647216
[TBL] [Abstract][Full Text] [Related]
18. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
Knaapila J; Jambor I; Perez IM; Ettala O; Taimen P; Verho J; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
Eur Urol Oncol; 2020 Oct; 3(5):648-656. PubMed ID: 31501082
[TBL] [Abstract][Full Text] [Related]
19. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
[TBL] [Abstract][Full Text] [Related]
20. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
